Skip To Main Content
Van Cutsem E on Muck Rack

Van Cutsem E

As seen in: Oxford University Press (OUP), PeerJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Van Cutsem E’s profile

Articles by Van Cutsem E

Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study

|
By Van Cutsem E, Bang YJ, Nanopep Biotech. Corp
| Oxford University Press (OUP)
Apatinib, a selective tyrosine kinase inhibitor for vascular endothelial growth factor receptor 2 (VEGFR2), is commonly used as a third-line treatment for patients with GC and has been authorized by the China Food and Drug Administration. Clinical studies have shown that combining immunotherapy with apatinib yields favorable antitumor activity and manageable safety.
Open in Who Shared Issue with article?

Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review

|
By Van Cutsem, Hospitals Gasthuisberg Leuven, KU Leuven, Van Cutsem E
| Oxford University Press (OUP)
Fluoropyrimidines, including 5-fluorouracil and capecitabine, alone or as part of combination regimens, have formed the mainstay in treating gastrointestinal cancers.1,2 However, resistance to fluoropyrimidines remains a considerable barrier to effective treatment.2 Trifluridine/tipiracil (FTD/TPI or TAS-102; Taiho Oncology, Inc., Princeton, NJ, USA) is an oral cytotoxic agent comprising trifluridine, a thymidine analog, and tipiracil, a thymidine phosphorylase inhibitor.3 FTD/TPI has a...
Open in Who Shared Issue with article?

Association between different types of preoperative anemia and tumor characteristics, systemic inflammation, and survival in colorectal cancer

|
By Byrd Dr, Logan RF, EL M, Van Cutsem E
| PeerJ
Throughout the electronic medical record, 95 patients who received surgical treatment in our hospital from February 2016 to January 2018 were chosen according to the inclusion criteria: (1) Patients who were diagnosed with CRC for the first time and underwent radical surgery; (2) pathologically confirmed as CRC; (3) patients who received the relevant index test within one week before the operation; (4) there are relatively complete clinical data and follow-up related information; exclusion...
Open in Who Shared Issue with article?

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

|
By Van Cutsem E, Amado RG, Freeman DJ, Patterson SD
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (590) Issue with article?

Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis

|
By Van Cutsem E, Van Aelst L
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (356) Issue with article?

18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

|
By Van Cutsem E, Deroose CM
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (369) Issue with article?

Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164 - PubMed

|
By Diaz LA, Kim TW, Van Cutsem E, Le DT
| ncbi.nlm.nih.gov
doi: 10.1016/j.ejca.2023.02.016. Online ahead of print. Affiliations Affiliations 1 Oncology, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore, MD, USA. Electronic address: dle@jhmi.edu. 2 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Oncology, Asan Medical Center, Seoul, Republic of Korea. 3 Oncology, Asan Medical Center, Seoul, Republic of Korea; University of Ulsan, Ulsan, Republic of Korea.
Open in Who Shared Issue with article?

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a

|
By Van Cutsem E, Di Bartolomeo M, Wainberg ZA
| ncbi.nlm.nih.gov
Skip to main page content Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software doi: 10.1016/S1470-2045(23)00215-2. Online ahead of print.
Open in Who Shared Issue with article?

Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

|
By Van Cutsem E, Van Laere K, Deroose CM, Clement PM
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (432) Issue with article?

Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study

|
By Van Cutsem E, Vanden Bempt I
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (521) Issue with article?

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study - PubMed

|
By Strickler JH, Van Cutsem E, Paulson AS, Hubbard JM
| ncbi.nlm.nih.gov
Skip to main page content Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software doi: 10.1016/S1470-2045(23)00150-X.
Open in Who Shared Issue with article?
Show More